GLIP-i-zide
Absorption: Well absorbed following oral administration.
Distribution: Unknown.
Protein Binding: 99%.
Half-Life: 2.1–2.6 hr.
Contraindicated in:
Use Cautiously in:
Derm: photosensitivity, rash
Endo: hypoglycemia
F and E: hyponatremia
GI: constipation, cramps, diarrhea, dyspepsia, hepatitis, nausea, vomiting
Hemat: agranulocytosis, APLASTIC ANEMIA, hemolytic anemia, leukopenia, pancytopenia, thrombocytopenia
Drug-drug:
Lab Test Considerations:
Toxicity and Overdose:
Accidental administration of oral hypoglycemic agents to non-diabetic adults and children has resulted in serious harm or death. Before administering, confirm that patient has Type 2 diabetes.
Do not confuse glipizide with glyburide.
NDC Code